TrialJournal of neuro-oncology2016

A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.

H Ian Robins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.